Wall Street analysts refresh ratings across tech, energy and biotech stocks
A broad set of Wall Street research calls on Thursday highlights continued investor focus on artificial intelligence, energy demand and selective healthcare growth. The recommendations span upgrades, new coverage and conviction list additions, with firms backing names including Amazon, Microsoft, Nvidia, BP and several biotech companies.
Highlights
- Bank of America reiterates Micron as buy after earnings, citing durable AI-driven memory demand and improved supply discipline, while Goldman Sachs upgrades TC Energy and Occidental Petroleum to buy.
- Wells Fargo upgrades BP to overweight and downgrades Exxon to equal weight, seeing greater upside for BP, and adds Microsoft to its Q4 tactical buy list.
- JPMorgan initiates Kura Oncology, Enliven Therapeutics, and Spyre Therapeutics at overweight with 2027 price targets, while Mizuho upgrades BJ’s Restaurants to outperform based on higher same-store sales.
Thursday rating changes across major sectors
As reported by CNBC, Thursday’s analyst calls include a mix of reiterated buy ratings, upgrades and initiations across technology, energy, consumer and healthcare stocks.Bank of America reiterates Micron as buy after earnings, citing a durable memory cycle tied to AI demand and tighter supply discipline. Goldman Sachs upgrades TC Energy to buy from neutral, arguing the recent share pullback looks excessive, and also upgrades Occidental Petroleum to buy from neutral while adding Amazon to its conviction buy list.
Wells Fargo upgrades BP to overweight from equal weight and downgrades Exxon to equal weight from overweight, saying it sees greater upside in BP. The bank also upgrades Consolidated Edison to overweight from equal weight and adds Microsoft to its fourth-quarter tactical buy list, while UBS reiterates Nvidia as buy and calls it a top idea for the quarter.
Elsewhere, Morgan Stanley initiates Toll Brothers as overweight and reiterates Apple as overweight, even as it trims its Apple price target. Deutsche Bank adds Meta to its fresh money list, Guggenheim reiterates Netflix as buy, and Loop upgrades Dollar Tree to buy from hold on what it calls a favorable economic backdrop.
Biotech and smaller-cap names draw new support
JPMorgan initiates Kura Oncology, Enliven Therapeutics and Spyre Therapeutics at overweight, pointing to the appeal of their pipelines and longer-term price targets extending into 2027. TD Cowen also initiates Teva Pharmaceuticals as buy, citing its combination of generic, biosimilar and innovative drug exposure.RBC initiates Digital Turbine as outperform, Oppenheimer starts Vita Coco at outperform, Roth begins coverage of Civeo with a buy rating, Citi initiates Rocket Lab as buy, and BMO starts National Energy Services Reunited at outperform. Mizuho upgrades BJ’s Restaurants to outperform from neutral on stronger same-store sales expectations, while Argus upgrades Regeneron to buy from hold after a recent share pullback.
The spread of calls suggests analysts remain willing to back both large-cap market leaders and smaller growth names, especially where firms see valuation support, sector-specific catalysts or exposure to themes such as AI infrastructure, energy resilience and specialized drug development.
Micron’s upbeat first-quarter outlook highlighted how strong AI-driven demand for high-bandwidth memory is lifting expectations across the semiconductor sector. Our earlier coverage noted that orders have outstripped Micron’s capacity, tightening supply and supporting broader chip pricing, following a sharp year-over-year jump in quarterly revenue and profit.